Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

VT1021

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Vigeo Therap

Drug class:

CD36 stimulant, TSP1 stimulant

Related drugs:

‹

NRT-YHD_001 (0)

NRT-YHD_001 (0)

›

CD36 overexpression	Solid Tumor	CD36 overexpression	Solid Tumor	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3
CD47 overexpression	Triple Negative Breast Cancer	CD47 overexpression	Triple Negative Breast Cancer	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3
CD47 overexpression	Glioblastoma	CD47 overexpression	Glioblastoma	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3
CD47 overexpression	Ovarian Cancer	CD47 overexpression	Ovarian Cancer	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3
CD36 overexpression	Glioblastoma	CD36 overexpression	Glioblastoma	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3
CD36 overexpression	Triple Negative Breast Cancer	CD36 overexpression	Triple Negative Breast Cancer	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3
CD36 overexpression + CD47 overexpression	Pancreatic Cancer	CD36 overexpression + CD47 overexpression	Pancreatic Cancer	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3
CD36 overexpression	Ovarian Cancer	CD36 overexpression	Ovarian Cancer	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3	VT1021 Sensitive: C3 – Early Trials VT1021 Sensitive : C3
CD47 overexpression	Solid Tumor	CD47 overexpression	Solid Tumor	VT1021 Sensitive: D – Preclinical VT1021 Sensitive : D	VT1021 Sensitive: D – Preclinical VT1021 Sensitive : D